HONG KONG – Having been developing basic fibroblast growth factor (bFGF) products for more than 25 years, China’s Essex Bio-technology Ltd. (HK:1061) has earned a leading position in the ophthalmology biopharmaceutical space. Now the company is looking to expand its offerings by moving into the rapidly growing monoclonal antibody space.